{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:56:26Z","timestamp":1740174986890,"version":"3.37.3"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bulcan.2023.12.016","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T20:23:56Z","timestamp":1709756636000},"page":"356-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyse des effets des inhibiteurs de l\u2019aromatase en traitement prolong\u00e9 chez les femmes m\u00e9nopaus\u00e9es atteintes d\u2019un cancer du sein non m\u00e9tastatique hormonod\u00e9pendant ayant d\u00e9j\u00e0 re\u00e7u cinq ans d\u2019hormonoth\u00e9rapie adjuvante\u00a0: revue syst\u00e9matique et m\u00e9ta-analyse"],"prefix":"10.1016","volume":"111","author":[{"given":"Kossi Cl\u00e9ment","family":"Trenou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5788-4984","authenticated-orcid":false,"given":"Miceline","family":"M\u00e9sidor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5355-7345","authenticated-orcid":false,"given":"Caroline","family":"Diorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-3314","authenticated-orcid":false,"given":"Denis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bulcan.2023.12.016_bib0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9869","key":"10.1016\/j.bulcan.2023.12.016_bib0100","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10\u00a0years versus stopping at 5\u00a0years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bulcan.2023.12.016_bib0105","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14\u00a0randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.bulcan.2023.12.016_bib0110","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"18_suppl","key":"10.1016\/j.bulcan.2023.12.016_bib0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10\u00a0years versus stopping at 5\u00a0years in 6,953\u00a0women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.12.016_bib0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jnci\/djx134","article-title":"Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)","volume":"110","author":"Blok","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.bulcan.2023.12.016_bib0125","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djm246","article-title":"Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a","volume":"99","author":"Jakesz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.bulcan.2023.12.016_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","article-title":"A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology\/NSABP B-42","volume":"20","author":"Mamounas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.12.016_bib0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-019-05464-w","article-title":"Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials","volume":"179","author":"Qian","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2023.12.016_bib0140","doi-asserted-by":"crossref","first-page":"1039320","DOI":"10.3389\/fonc.2022.1039320","article-title":"Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"year":"2019","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","key":"10.1016\/j.bulcan.2023.12.016_bib0145"},{"issue":"2","key":"10.1016\/j.bulcan.2023.12.016_bib0150","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"J Med Libr Assoc"},{"issue":"1","key":"10.1016\/j.bulcan.2023.12.016_bib0155","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"J Med Libr Assoc"},{"issue":"7414","key":"10.1016\/j.bulcan.2023.12.016_bib0160","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.bulcan.2023.12.016_bib0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10\u00a0years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2023.12.016_bib0170","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","article-title":"Benefit from exemestane as extended adjuvant therapy after 5\u00a0years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33\u00a0trial","volume":"26","author":"Mamounas","year":"2008","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2023.12.016_bib0175","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1200\/JCO.22.00577","article-title":"Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial","volume":"41","author":"Iwase","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.12.016_bib0090","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/annonc\/mdw055","article-title":"Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501\u00a0LATER): an open-label randomised, controlled trial\u2020","volume":"27","author":"Zdenkowski","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T08:59:17Z","timestamp":1711184357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0007455124000511"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.12.016","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyse des effets des inhibiteurs de l\u2019aromatase en traitement prolong\u00e9 chez les femmes m\u00e9nopaus\u00e9es atteintes d\u2019un cancer du sein non m\u00e9tastatique hormonod\u00e9pendant ayant d\u00e9j\u00e0 re\u00e7u cinq ans d\u2019hormonoth\u00e9rapie adjuvante\u00a0: revue syst\u00e9matique et m\u00e9ta-analyse","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}